Learning from our mistakes: Using key opportunities to remove the perverse incentives that help drive antibiotic resistance.

Learning from our mistakes: Using key opportunities to remove the perverse incentives that help drive antibiotic resistance. Expert Rev Pharmacoecon Outcomes Res. 2019 Dec 17;: Authors: Edwards SE, Morel CM Abstract INTRODUCTION: Governments need to do far more to help curb the emergence and transmission of antibiotic resistance and help protect the efficacy of any new antibiotics that come to market. Industry is an important stakeholder that must be brought on-board such efforts given its influence on the direction and scale of antibiotic sales. Financial incentives supporting industry R&D of novel antibiotics should structurally remove the drivers of superfluous sales and encourage access to newer antibiotics where infections are otherwise resistant to treatment. Indeed the use of public money provides an important opportunity to prioritize these public health goals within market structures such that we both generously reward industry for their efforts and prolong antibiotic efficacy for as long as possible.Areas covered: This work discusses possible financial "pull" incentives that fully delink the reward paid to the developer from unit sales, examining their primary advantages and limitations.Expert opinion: Pharmaceutical companies need to be rewarded generously for their efforts to develop new, badly needed antibiotics. But the current marketplace does not provide a sustained financial lure and its reliance on unit-sales fo...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research